Praxbind

Active Ingredient(s): Idarucizumab
FDA Approved: * October 16, 2015
Pharm Company: * BOEHRINGER INGELHEIM
Category: Blood Clotting (Hemostasis)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Praxbind Overview

Idarucizumab (BI 655075), sold under the brand name Praxbind, is a monoclonal antibody designed for the reversal of anticoagulant effects of dabigatran.[1][2] This drug was developed by Boehringer Ingelheim Pharmaceuticals. A large study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation by dabigatran within minutes.[3] It was FDA approved in October 2015.[4] In the United States the wholes...

Read more Praxbind Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Idarucizumab

Recent Praxbind Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Praxbind: (1 result)

Sorted by National Drug Code

• 0597-0197 Praxbind 2.5 g/ml Intravenous Injection by Boehringer Ingelheim Pharmaceuticals, Inc.

Other drugs which contain Idarucizumab or a similar ingredient: (1 result)

• IDARUCIZUMAB